Annexon (ANNX) Free Cash Flow (2019 - 2026)
Annexon (ANNX) posted quarterly Free Cash Flow of -$46.5 million for Q1 2026, up 7.2% year-over-year from -$43.4 million in Q1 2025, and up 8.96% quarter-over-quarter from -$51.1 million in Q4 2025.
Annexon (ANNX) Free Cash Flow (2019 - 2026) Analysis & Trends
Annexon's Free Cash Flow history runs 8 years deep, the most recent figure standing at -$46.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.2% year-over-year to -$46.5 million; the TTM figure through Mar 2026 stood at -$188.1 million (down 34.45% YoY), while the FY2025 annual figure was -$191.7 million, down 62.4% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$46.5 million, up from -$51.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$21.7 million in Q2 2024, with the low at -$52.4 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$33.0 million (2023), against an average of -$35.0 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 40.59% in 2024, then sank 75.44% in 2025.
- Annexon's Free Cash Flow stood at -$27.1 million in 2022, then grew by 13.44% to -$23.5 million in 2023, then plunged by 53.39% to -$36.0 million in 2024, then slumped by 41.86% to -$51.1 million in 2025, then advanced by 8.96% to -$46.5 million in 2026.
- Business Quant data shows ANNX's Free Cash Flow at -$46.5 million in Q1 2026, -$51.1 million in Q4 2025, and -$52.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | -48.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.01 Mn |
| Jun 30, 2026 | -48.01 Mn |
| Mar 31, 2026 | -46.52 Mn |
| Mar 31, 2026 | -46.52 Mn |
| Dec 31, 2025 | -51.10 Mn |
| Dec 31, 2025 | -51.10 Mn |
| Sep 30, 2025 | -52.35 Mn |
| Sep 30, 2025 | -52.35 Mn |
| Jun 30, 2025 | -38.09 Mn |
| Jun 30, 2025 | -38.09 Mn |
| Mar 31, 2025 | -50.13 Mn |
| Mar 31, 2025 | -50.13 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Sep 30, 2024 | -32.02 Mn |
| Sep 30, 2024 | -32.02 Mn |
| Jun 30, 2024 | -21.71 Mn |
| Jun 30, 2024 | -21.71 Mn |
| Mar 31, 2024 | -28.63 Mn |
| Mar 31, 2024 | -28.63 Mn |